Eric Swayze, EVP Research at IONIS PHARMACEUTICALS INC (IONS), sold 378 shares at $44.15 ($17K) on 2022-04-21, disclosed to the SEC on 2022-04-25.
Scheduled sale ($17k) by EVP Research under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| Filing → |
| IONS | SELL | 2026-02-02 | $512K | — | Filing → |
| IONS | SELL | 2026-01-20 | $748K | — | Filing → |
| IONS | SELL | 2026-01-06 | $1.9M | — | Filing → |